Table 3. Cox proportional hazard models for all-cause mortality introducing achieved HbA1c, SBP, or LDL-C as updated, cumulative, yearly mean values.
Hazard ratio (95% CI) | P value | Hazard ratio (95% CI) | P value | |
HbA1c (%)* | Model 1 | Model 2 | ||
<6.0 | 1.21 (1.02–1.44) | 0.033 | 1.27 (1.06–1.51) | 0.008 |
6.0–7.0 | 0.86 (0.77–0.97) | 0.011 | 0.93 (0.83–1.04) | 0.21 |
7.0–8.0 | 0.76 (0.68–0.84) | <0.001 | 0.77 (0.69–0.85) | <0.001 |
8.0–9.0 | 0.94 (0.83–1.05) | 0.25 | 0.92 (0.82–1.03) | 0.16 |
9.0–10.0 | 1.04 (0.90–1.21) | 0.6 | 0.98 (0.84–1.13) | 0.7 |
≥10.0 | 1.30 (1.12–1.50) | 0.001 | 1.23 (1.06–1.43) | 0.006 |
SBP (mmHg)* | Model 3 | Model 4 | ||
<120 | 0.92 (0.76–1.13) | 0.4 | 0.98 (0.80–1.20) | 0.8 |
120–130 | 1.02 (0.90–1.15) | 0.8 | 1.06 (0.94–1.19) | 0.4 |
130–140 | 0.96 (0.86–1.07) | 0.4 | 0.93 (0.84–1.04) | 0.23 |
140–150 | 0.98 (0.86–1.11) | 0.7 | 0.95 (0.84–1.08) | 0.4 |
150–160 | 1.10 (0.91–1.32) | 0.32 | 1.06 (0.88–1.28) | 0.5 |
≥160 | 1.04 (0.79–1.36) | 0.8 | 1.03 (0.78–1.35) | 0.9 |
LDL-C (mg/dL)* | Model 5 | Model 6 | ||
<70 | 1.33 (1.14–1.56) | <0.001 | 1.26 (1.08–1.47) | 0.004 |
70–100 | 0.87 (0.78–0.97) | 0.009 | 0.85 (0.77–0.94) | 0.002 |
100–130 | 0.75 (0.68–0.83) | <0.001 | 0.77 (0.70–0.85) | <0.001 |
130–160 | 0.84 (0.74–0.95) | 0.007 | 0.87 (0.77–0.99) | 0.034 |
≥160 | 1.37 (1.15–1.62) | <0.001 | 1.39 (1.17–1.66) | <0.001 |
The models used Cox proportional hazards regression analyses adjusted for potential confounders. The hazard ratios relative to the population mean were calculated.
*HbA1c, SBP, or LDL-C was introduced in an updated, cumulative, yearly mean value (with the last observation carried forward for missing data).
Model 1 adjusted for age, sex, mean SBP, and LDL-C.
Model 3 adjusted for age, sex, mean HbA1c, and LDL-C.
Model 5 adjusted for age, sex, mean HbA1c, and SBP.
Model 2,4,6 included the confounders in model 1,2,3, respectively, plus pre-existing myocardial infarction, congestive heart failure, stroke, malignant neoplasm, chronic kidney disease, use of insulin, any anti-hypertensive drug, any lipid-lowering drug, and antiplatelet.